Shockwave Medical (Shockwave Medical) ROCE % : 16.35% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Shockwave Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shockwave Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was 16.35%.

Shockwave Medical ROCE % Historical Data

The historical data trend for Shockwave Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shockwave Medical ROCE % Chart

Shockwave Medical Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-39.77

-28.35

-2.86

27.99

17.72

Shockwave Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															36.34	27.04	20.07	18.11	16.35

Shockwave Medical ROCE % Calculation

Shockwave Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	181.186	/	( ( (646.089 - 63.374)	+	(1566.563 - 104.205) )	/ 2 )
	=	181.186	/	( (582.715	+	1462.358)	/ 2 )
	=	181.186	/	1022.5365
	=	17.72 %

Shockwave Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	233.64	/	( ( (1473.959 - 78.203)	+	(1566.563 - 104.205) )	/ 2 )
	=	233.64	/	( ( 1395.756	+	1462.358 )	/ 2 )
	=	233.64	/	1429.057
	=	16.35 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Shockwave Medical (NAS:SWAV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shockwave Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Shockwave Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shockwave Medical (Shockwave Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shockwave Medical Inc (NAS:SWAV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

36M:Germany 36M:Germany

Address

5403 Betsy Ross Drive, Santa Clara, CA, USA, 95054

Website

https://www.shockwavemedical.com

ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States, Europe and other countries.

Executives

Douglas Evan Godshall	director, officer: President & CEO	SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Frank T Watkins	director	5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Isaac Zacharias	officer: Chief Commercial Officer	5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Dan Puckett	officer: CFO & Secretary	5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Trinh Phung	officer: VP, Finance	C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Laura Francis	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Sara Toyloy	director	C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Kevin J. Ballinger	director	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Antoine Papiernik	director, 10 percent owner	5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Sofinnova Capital Vii Fcpr	10 percent owner	C/O SOFINNOVA PARTNERS, 18 RUE DU 4 SEPTEMBRE, 75002 PARIS I0 00000
Cahill Colin	director	5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Frederic H Moll	director	C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Larkin C Raymond Jr	director	C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105